Janssen takes Genmab's daratumumab into Phase III
This article was originally published in Scrip
Executive Summary
Genmab's partner Janssen Biotech is to start Phase III development of daratumumab in relapsed or refractory multiple myeloma. Three months ago Genmab said it had received an $8m milestone payment from Janssen for "progress in clinical development," although what that progress was remained undisclosed (scripintelligence.com, 26 November 2013).